CTIA Members Committed To Protecting Patient Privacy
CTIA highlighted the role its members play in pushing the envelope on mobile health and said in comments to the FDA that the wireless industry is well aware of the importance of protecting consumer privacy. The filing was on part…
Sign up for a free preview to unlock the rest of this article
Export Compliance Daily combines U.S. export control news, foreign border import regulation and policy developments into a single daily information service that reliably informs its trade professional readers about important current issues affecting their operations.
of an agency request for comments on “Using Technologies and Innovative Methods to Conduct Food and Drug Administration-Regulated Clinical Investigations of Investigational Drugs.” The average U.S. home has 5.3 connected devices and Americans use more than 11.1 billion MBs of mobile data every day, CTIA said. “The ubiquity of powerful mobile devices, along with their ever-expanding array of sophisticated features and availability of health-related software, creates opportunities to revolutionize clinical trials.” CTIA cited AT&T’s work with the Garrison Geriatric Education and Care Center at Texas Tech University to provide connectivity to embedded pressure sensors and accelerometers in shoe inserts, which gather data in a fall-risk study. Duke University is using Verizon-enabled activity monitors and glucometers to analyze the impact of physical activity on participants with peripheral arterial disease, CTIA said. CTIA and its members understand the importance of protecting patient privacy, the wireless association said. “Protecting clinical trial participant data privacy is a top priority for the wireless industry, which implements a variety of options for consumers to choose when and with whom they share data. More generally, our industry participates in ongoing dialogue with policymakers, privacy advocates, and the health sector to ensure compliance with applicable regulations and norms aimed at protecting health data privacy.” Comments were in docket FDA-201-N-3579.